{"id":28149,"date":"2026-03-18T17:33:19","date_gmt":"2026-03-18T12:03:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28149"},"modified":"2026-03-25T13:19:30","modified_gmt":"2026-03-25T07:49:30","slug":"emerging-therapies-for-retinal-vein-occlusion-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment","title":{"rendered":"Emerging Therapies for Retinal Vein Occlusion Treatment: What Lies Ahead?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1281648405f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1281648405f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment\/#%E2%80%8BAnti-VEGF_Therapies_The_Backbone_of_RVO_Treatment\" >\u200bAnti-VEGF Therapies: The Backbone of RVO Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment\/#New_Treatments_for_Retinal_Vein_Occlusion_in_Horizon\" >New Treatments for Retinal Vein Occlusion in Horizon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment\/#Future_RVO_Treatment_Space_Looks_Promising\" >Future RVO Treatment Space Looks Promising<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy and primarily affects people <strong>over 65<\/strong>, making aging a key driver of disease burden and of the growing retinal vascular occlusion market. RVO is broadly classified into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), with CRVO further divided into ischemic and non\u2011ischemic forms based on perfusion, and BRVO including major and macular branch involvement.<\/p>\n\n\n\n<p>In 2024, there were an estimated <strong>2.7 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinal-vein-occlusion-epidemiology-forecast\">prevalent RVO cases<\/a> across the 7MM, with around <strong>170,000<\/strong> CRVO and <strong>765,000<\/strong> BRVO cases in the US alone, highlighting the size and growth potential of the retinal vein occlusion market and retinal vascular occlusion therapeutics market. Because blocked veins cannot be mechanically reopened, the focus of treatment for retinal vein occlusion is on stabilizing vision, controlling macular edema, and preventing complications rather than providing a definitive \u201ccrvo cure\u201d or complete reversal of central retinal vein occlusion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E2%80%8BAnti-VEGF_Therapies_The_Backbone_of_RVO_Treatment\"><\/span>\u200b<strong>Anti-VEGF Therapies: The Backbone of RVO Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>From a clinical standpoint, can retinal vein occlusion be cured, or can central retinal vein occlusion be cured? At present, there is no approved therapy that reverses the underlying venous obstruction, so most patients are left with some permanent visual changes despite appropriate retinal vascular occlusion treatment. As a result, answers to questions like can retinal vein occlusion be reversed or can crvo be reversed remain cautious: some eyes show visual improvement over time, some remain stable, and others worsen, with roughly one\u2011third in each category, and recovery potentially taking more than a year.<\/p>\n\n\n\n<p>\u200bGiven this reality, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/central-retinal-vein-occlusion-market\">best treatment for central retinal vein occlusion<\/a> or branch disease is early, sustained management of macular edema and risk factors using retinal vein occlusion treatment injection strategies, laser, and systemic control, rather than expecting a true CRVO cure. This positioning is crucial both for patient counseling and for framing value propositions in the retinal vein occlusion therapeutics market and the retinal vein occlusion treatment market.<\/p>\n\n\n\n<p>Today\u2019s standard retinal vein occlusion treatment relies on intravitreal anti\u2011VEGF agents and corticosteroids, which form the backbone of both clinical practice and the US retinal vein occlusion market. Key approved drugs in the retinal vein occlusion treatment injection class include <strong>LUCENTIS<\/strong> (ranibizumab), <strong>EYLEA <\/strong>(aflibercept), <strong>OZURDEX <\/strong>(dexamethasone intravitreal implant), and the newer <strong>VABYSMO <\/strong>(faricimab), while <strong>AVASTIN <\/strong>(bevacizumab) and intravitreal triamcinolone remain widely used off\u2011label eye injections for RVO and other retinal vascular obstruction treatment needs.<\/p>\n\n\n\n<p>AVASTIN for retinal vein occlusion, though off\u2011label, remains a cost\u2011effective retinal disease treatment option for RVO in many settings, particularly where access or pricing is a concern. This mix of branded biologics, implants, and off\u2011label agents defines what\u2019s the current <a href=\"https:\/\/www.delveinsight.com\/report-store\/vegf-inhibitors-market-forecast\">anti\u2011VEGF treatment landscape<\/a> for RVO, especially in high\u2011volume centers such as retinal vascular occlusion treatment downtown clinics in global metros.<\/p>\n\n\n\n<p><em>Sadaf Javed, Manager of Forecasting at DelveInsight, said that RVO management is evolving toward more personalized approaches, combining established anti-VEGF therapies with next-generation treatments that offer longer durability, reduced injection frequency, and better long-term visual outcomes for patients.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-new-treatments-for-retinal-vein-occlusion-in-horizon\"><span class=\"ez-toc-section\" id=\"New_Treatments_for_Retinal_Vein_Occlusion_in_Horizon\"><\/span><strong>New Treatments for Retinal Vein Occlusion in Horizon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A robust pipeline of new treatments for retinal vein occlusion is expected to reshape both clinical practice and the broader retinal vascular occlusion market over the next decade. These new treatments for retinal vein occlusion aim to extend dosing intervals, improve anatomical and functional outcomes, and, ultimately, move closer to disease modification for both branch retinal vein occlusion and central retinal vein occlusion.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"274\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies-1024x274.webp\" alt=\"Retinal-Vein-Occlusion-Emerging-Therapies\" class=\"wp-image-34740\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies-1024x274.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies-300x80.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies-150x40.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies-768x205.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies-1536x410.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Emerging-Therapies.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Some of the promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinal-vein-occlusion-pipeline-insight\">emerging RVO drugs in clinical trials<\/a> include <strong>Tarcocimab tedromer (KSI-301)<\/strong> (Kodiak Sciences), <strong>LYTENAVA (ONS-5010)<\/strong> (Outlook Therapeutics), <strong>ANXV<\/strong> (Annexin Pharmaceuticals), and others. Tarcocimab tedromer (KSI-301), developed by Kodiak Sciences, is an intravitreal therapy and a next-generation anti-VEGF biologic designed for extended activity within the eye. It integrates a customized anti-VEGF antibody with a phosphorylcholine-based biopolymer to target VEGF, a central factor in retinal vascular disorders. Built on the Antibody Biopolymer Conjugate (ABC) platform, the therapy aims to enhance drug durability in ocular tissues, maintaining therapeutic levels for longer periods than currently available treatments.<\/p>\n\n\n\n<p>In September 2023, Kodiak Sciences announced top-line findings from the <strong>BEACON study<\/strong>, a pivotal trial assessing tarcocimab tedromer (5 mg). The 48-week results focused on patients with macular edema secondary to RVO. The company intends to file a single Biologics License Application (BLA) in 2026, combining data across three major retinal diseases, including RVO. This strategy underscores its goal to streamline the regulatory pathway and broaden its presence in the retinal disease market, with a potential launch anticipated in 2027 for RVO.<\/p>\n\n\n\n<p>ONS-5010\/LYTENAVA is a U.S.-manufactured ophthalmic formulation of bevacizumab designed to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/wet-age-related-macular-degeneration-wet-amd-market\">wet age-related macular degeneration (AMD)<\/a>. It has received centralized marketing authorization from the European Commission for use in the EU, as well as approval from the UK\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for the same indication. However, in some EU countries, additional pricing and reimbursement approvals are required before commercialization.<\/p>\n\n\n\n<p>In March 2026, the company shared an update following a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) issued on December 30, 2025, for its Biologics License Application (BLA). The meeting focused on addressing the FDA\u2019s concerns about demonstrating substantial evidence of effectiveness and exploring possible pathways to secure regulatory approval.<\/p>\n\n\n\n<p>Clinical data showed that ONS-5010\/LYTENAVA achieved statistically significant and clinically meaningful improvements in visual acuity in the <strong>Phase 3 NORSE TWO trial<\/strong>, successfully meeting both primary and key secondary endpoints. Additional support from the <strong>NORSE EIGHT study <\/strong>and other BLA submissions reinforced its efficacy and safety, including evidence aligned with its anti-VEGF mechanism of action. The therapy also exhibited a favorable safety profile, with no major concerns raised by the FDA.<\/p>\n\n\n\n<p>If approved, ONS-5010\/LYTENAVA would become the first FDA-approved ophthalmic formulation of bevacizumab backed by standardized manufacturing, approved labeling, and comprehensive pharmacovigilance.<\/p>\n\n\n\n<p>ANXV is an experimental biologic developed by Annexin Pharmaceuticals, derived from the human protein Annexin A5. It is produced using recombinant DNA technology by inserting the Annexin A5 gene into E. coli, allowing scalable protein manufacturing through microbial expression systems.<\/p>\n\n\n\n<p>In August 2024, the company announced positive topline data from a Phase IIa study of ANXV in RVO, demonstrating a favorable safety profile and clinical improvement in most patients, along with reduced reliance on anti-VEGF therapy.<\/p>\n\n\n\n<p>These programs, although nascent, underscore how the future retinal vein occlusion therapeutics market may look very different, with regenerative concepts added to the current anti\u2011VEGF and steroid paradigm.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_RVO_Treatment_Space_Looks_Promising\"><\/span><strong>Future RVO Treatment Space Looks Promising<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinal-vein-occlusion-market\">retinal vein occlusion market<\/a> and the more focused retinal vein occlusion treatment market are expected to expand as prevalence rises with aging populations and as multiple new entrants launch across both biologics and small implants. Patent expiries for legacy agents, together with the introduction of biosimilars such as <strong>BYOOVIZ and ONGAVIA<\/strong>, will intensify price competition and widen access, but also increase barriers for premium\u2011priced newcomers in the retinal vascular occlusion therapeutics market.<\/p>\n\n\n\n<p>For health systems and providers, this evolving mix creates opportunities to design cost\u2011effective retinal disease treatment options for RVO, balancing branded anti\u2011VEGF agents, biosimilars, implants, and off\u2011label AVASTIN for retinal vein occlusion to tailor regimens by indication, such as BRVO versus CRVO treatment. Markets such as the US retinal vein occlusion market and geographies like Turkey retinal vascular occlusion treatment centers, where interest in transparent Turkey retinal vascular occlusion treatment prices is rising, will be closely watched as testbeds for novel reimbursement and access models.<\/p>\n\n\n\n<p>Across global hubs, including \u201cretinal vein occlusion treatment downtown\u201d clinics and specialized \u201ccentral retinal vein occlusion treatment downtown\u201d centers, clinicians will increasingly have a wider menu of retinal occlusion treatment injection options and RVO injection schedules to individualize care. In parallel, targeted segments such as \u201cbest treatment for central retinal vein occlusion downtown\u201d or \u201ctreatment for CRVO\u201d will remain highly competitive as payers seek value and patients seek therapies that come closer to answering whether retinal vein occlusion can be cured or whether CRVO treatment can truly change the long\u2011term visual trajectory.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/retinal-vein-occlusion-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment-1024x194.webp\" alt=\"Retinal Vein Occlusion Market Outlook and Assessment\" class=\"wp-image-34739\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/Retinal-Vein-Occlusion-Market-Outlook-and-Assessment.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1760092641480\"><strong class=\"schema-faq-question\"><strong>What are the most promising new treatments in development for retinal vein occlusion (RVO)?<\/strong><\/strong> <p class=\"schema-faq-answer\">Some of the promising new treatments for RVO in clinical trials include Tarcocimab tedromer (KSI-301) (Kodiak Sciences), LYTENAVA (ONS-5010) (Outlook Therapeutics), ANXV (Annexin Pharmaceuticals), and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760092647495\"><strong class=\"schema-faq-question\"><strong>How do emerging RVO therapies differ from current standard treatments like anti\u2011VEGF injections?<\/strong><\/strong> <p class=\"schema-faq-answer\">Emerging therapies for RVO are designed to go beyond frequent anti-VEGF injections by targeting additional disease pathways such as inflammation, fibrosis, and vascular stability. Many of these next-generation approaches aim to provide longer-lasting effects through sustained delivery systems, gene therapies, or novel biologics, potentially reducing treatment burden and improving patient outcomes.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760092657762\"><strong class=\"schema-faq-question\"><strong>Are there any investigational gene or cell\u2011based therapies for retinal vein occlusion, and what is their potential timeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">Yes, early-stage cell-based and gene-adjacent approaches are being explored for RVO, but they remain largely investigational. Small studies have evaluated autologous CD34+ stem cell therapies for vascular repair, and while true gene therapies are not yet advanced specifically for RVO, adjacent retinal gene therapy platforms could eventually be adapted.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760092671856\"><strong class=\"schema-faq-question\"><strong>What challenges do emerging RVO treatments aim to solve compared to existing therapies?<\/strong><\/strong> <p class=\"schema-faq-answer\">Emerging treatments for RVO aim to address key limitations of current therapies, such as the need for frequent intravitreal injections and variable patient response. They focus on improving durability, targeting underlying disease mechanisms beyond VEGF, and delivering more consistent visual outcomes with reduced treatment burden.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1773835117619\"><strong class=\"schema-faq-question\">When might patients expect the newest RVO treatments to become clinically available or FDA\u2011approved?<\/strong> <p class=\"schema-faq-answer\">Most pipeline therapies are still in mid- to late-stage trials, suggesting broader clinical availability and FDA approvals will likely emerge over the next 2\u20135 years, depending on trial outcomes and regulatory timelines.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy and primarily affects people over 65, making aging a key driver of disease burden and of the growing retinal vascular occlusion market. RVO is broadly classified into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), with CRVO further [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28151,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1102,1103,16762,16760,16759,16764,16761,21429],"industry":[],"therapeutic_areas":[],"class_list":["post-28149","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-eylea","tag-lucentis","tag-retinal-vein-occlusion","tag-retinal-vein-occlusion-drug-market","tag-retinal-vein-occlusion-market","tag-retinal-vein-occlusion-pipeline","tag-retinal-vein-occlusion-treatment-market","tag-vabysmo"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Retinal Vein Occlusion Treatment: A Glimpse into Future Therapies<\/title>\n<meta name=\"description\" content=\"Potential therapies are being investigated for retinal vein occlusion treatment and, it is safe to assume that future of market is promising.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retinal Vein Occlusion Treatment: A Glimpse into Future Therapies\" \/>\n<meta property=\"og:description\" content=\"Potential therapies are being investigated for retinal vein occlusion treatment and, it is safe to assume that future of market is promising.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T12:03:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T07:49:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/27152247\/emerging-therapies-for-retinal-vein-occlusion-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retinal Vein Occlusion Treatment: A Glimpse into Future Therapies","description":"Potential therapies are being investigated for retinal vein occlusion treatment and, it is safe to assume that future of market is promising.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment","og_locale":"en_US","og_type":"article","og_title":"Retinal Vein Occlusion Treatment: A Glimpse into Future Therapies","og_description":"Potential therapies are being investigated for retinal vein occlusion treatment and, it is safe to assume that future of market is promising.","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-18T12:03:19+00:00","article_modified_time":"2026-03-25T07:49:30+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/27152247\/emerging-therapies-for-retinal-vein-occlusion-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment","url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment","name":"Retinal Vein Occlusion Treatment: A Glimpse into Future Therapies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/27152247\/emerging-therapies-for-retinal-vein-occlusion-treatment.png","datePublished":"2026-03-18T12:03:19+00:00","dateModified":"2026-03-25T07:49:30+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Potential therapies are being investigated for retinal vein occlusion treatment and, it is safe to assume that future of market is promising.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092641480"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092647495"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092657762"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092671856"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1773835117619"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/27152247\/emerging-therapies-for-retinal-vein-occlusion-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/27152247\/emerging-therapies-for-retinal-vein-occlusion-treatment.png","width":466,"height":284,"caption":"emerging-therapies-for-retinal-vein-occlusion-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092641480","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092641480","name":"What are the most promising new treatments in development for retinal vein occlusion (RVO)?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Some of the promising new treatments for RVO in clinical trials include Tarcocimab tedromer (KSI-301) (Kodiak Sciences), LYTENAVA (ONS-5010) (Outlook Therapeutics), ANXV (Annexin Pharmaceuticals), and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092647495","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092647495","name":"How do emerging RVO therapies differ from current standard treatments like anti\u2011VEGF injections?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Emerging therapies for RVO are designed to go beyond frequent anti-VEGF injections by targeting additional disease pathways such as inflammation, fibrosis, and vascular stability. Many of these next-generation approaches aim to provide longer-lasting effects through sustained delivery systems, gene therapies, or novel biologics, potentially reducing treatment burden and improving patient outcomes.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092657762","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092657762","name":"Are there any investigational gene or cell\u2011based therapies for retinal vein occlusion, and what is their potential timeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Yes, early-stage cell-based and gene-adjacent approaches are being explored for RVO, but they remain largely investigational. Small studies have evaluated autologous CD34+ stem cell therapies for vascular repair, and while true gene therapies are not yet advanced specifically for RVO, adjacent retinal gene therapy platforms could eventually be adapted.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092671856","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1760092671856","name":"What challenges do emerging RVO treatments aim to solve compared to existing therapies?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Emerging treatments for RVO aim to address key limitations of current therapies, such as the need for frequent intravitreal injections and variable patient response. They focus on improving durability, targeting underlying disease mechanisms beyond VEGF, and delivering more consistent visual outcomes with reduced treatment burden.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1773835117619","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-retinal-vein-occlusion-treatment#faq-question-1773835117619","name":"When might patients expect the newest RVO treatments to become clinically available or FDA\u2011approved?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Most pipeline therapies are still in mid- to late-stage trials, suggesting broader clinical availability and FDA approvals will likely emerge over the next 2\u20135 years, depending on trial outcomes and regulatory timelines.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/27152247\/emerging-therapies-for-retinal-vein-occlusion-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eylea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lucentis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Retinal vein occlusion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Retinal vein occlusion drug market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Retinal vein occlusion market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Retinal vein occlusion pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Retinal vein occlusion treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vabysmo<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Eylea<\/span>","<span class=\"advgb-post-tax-term\">Lucentis<\/span>","<span class=\"advgb-post-tax-term\">Retinal vein occlusion<\/span>","<span class=\"advgb-post-tax-term\">Retinal vein occlusion drug market<\/span>","<span class=\"advgb-post-tax-term\">Retinal vein occlusion market<\/span>","<span class=\"advgb-post-tax-term\">Retinal vein occlusion pipeline<\/span>","<span class=\"advgb-post-tax-term\">Retinal vein occlusion treatment market<\/span>","<span class=\"advgb-post-tax-term\">Vabysmo<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 2 months ago"},"absolute_dates":{"created":"Posted on Mar 18, 2026","modified":"Updated on Mar 25, 2026"},"absolute_dates_time":{"created":"Posted on Mar 18, 2026 5:33 pm","modified":"Updated on Mar 25, 2026 1:19 pm"},"featured_img_caption":"emerging-therapies-for-retinal-vein-occlusion-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28149"}],"version-history":[{"count":7,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28149\/revisions"}],"predecessor-version":[{"id":34855,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28149\/revisions\/34855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28151"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28149"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28149"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}